Novo Nordisk completes DKK 3.8B share buyback

Novo Nordisk A/S has completed a DKK 3,799,999,990 B-share repurchase tranche under its previously announced programme running from 4 February to 4 May 2026.

Rhea-AI Filing Summary

Novo Nordisk A/S has completed a DKK 3,799,999,990 B-share repurchase tranche under its previously announced programme running from 4 February to 4 May 2026. The company bought 14,759,179 B shares at an average price of DKK 257.47 per share.

After these transactions, Novo Nordisk holds 32,148,978 B shares of DKK 0.10 as treasury shares, equal to 0.7% of its 4,465,000,000 total A and B shares. This tranche is part of a wider plan to repurchase up to DKK 15 billion of B shares over a 12‑month period beginning 4 February 2026.

Key Figures

Repurchase value this tranche: DKK 3,799,999,990 B shares repurchased: 14,759,179 shares Average repurchase price: DKK 257.47 per B share +4 more

7 metrics

Repurchase value this tranche DKK 3,799,999,990 B-share buyback from 4 February to 4 May 2026

B shares repurchased 14,759,179 shares Total B shares bought under this tranche

Average repurchase price DKK 257.47 per B share Average price paid for 14,759,179 B shares

Planned total buyback DKK 15 billion Expected B-share repurchases over 12 months from 4 February 2026

Treasury B shares 32,148,978 shares B shares held as treasury shares after this tranche

Treasury share percentage 0.7% Treasury shares as a share of total share capital

Total A and B shares 4,465,000,000 shares Total share count including treasury shares

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, Regulation No 596/2014 (MAR), +1 more

5 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"Novo Nordisk owns a total of 32,148,978 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules")"

Regulation No 596/2014 (MAR) regulatory

"in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council"

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Novo Nordisk (NVO) announce in this Form 6-K?

Novo Nordisk announced completion of a B-share repurchase tranche totalling DKK 3,799,999,990. Between 4 February and 4 May 2026, it bought 14,759,179 B shares as part of a broader programme of up to DKK 15 billion.

How many Novo Nordisk (NVO) shares were repurchased in this tranche?

Novo Nordisk repurchased 14,759,179 B shares in this tranche. The company paid an average price of DKK 257.47 per B share, resulting in a total transaction value of DKK 3,799,999,990 during the period from 4 February to 4 May 2026.

What percentage of Novo Nordisk (NVO) share capital is held as treasury shares?

Novo Nordisk now holds 32,148,978 B shares as treasury shares, corresponding to 0.7% of its share capital. The total number of A and B shares in the company is 4,465,000,000, including these treasury shares accumulated through the share repurchase programme.

What is the total size of Novo Nordisk’s (NVO) ongoing buyback programme?

Novo Nordisk expects to repurchase B shares for up to DKK 15 billion over a 12-month period beginning 4 February 2026. The completed DKK 3,799,999,990 tranche forms part of this larger overall share repurchase programme authorised by the company.

Under what regulatory framework is Novo Nordisk’s (NVO) buyback conducted?

The repurchase is carried out under Article 5 of Regulation No 596/2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, referred to as the Safe Harbour Rules. These European regulations set conditions for market buybacks and help limit market abuse concerns.

Where can investors find detailed daily transactions for Novo Nordisk (NVO) buybacks?

Detailed information on each transaction under Novo Nordisk’s buyback programme is published on novonordisk.com. The company lists daily numbers of B shares repurchased, average purchase prices and transaction values, allowing investors to track the programme’s execution over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 09:30 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

May 5, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 5 May 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026. The programme is now concluded.

Since the announcement 27 April 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	13,407,992		3,438,931,195
27 April 2026	230,000	260.37	59,884,786
28 April 2026	230,000	263.34	60,567,237
29 April 2026	230,000	260.53	59,921,977
30 April 2026	230,000	264.07	60,735,091
1 May 2026	230,000	274.85	63,216,000
4 May 2026	201,187	282.04	56,743,704
Accumulated under the programme	14,759,179		3,799,999,990

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Page 2 of 2

With the transactions stated above, Novo Nordisk owns a total of 32,148,978 B shares of DKK 0.10 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12- month period beginning 4 February 2026. As of 4 May 2026, Novo Nordisk has since 4 February 2026 repurchased a total 14,759,179 B shares at an average share price of DKK 257.47 per B share equal to a transaction value of DKK 3,799,999,990.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:		Liz Skrbkova (US)
Ambre James-Brown		+1 609 917 0632
+45 3079 9289		lzsk@novonordisk.com
globalmedia@novonordisk.com
Investors:
Michael Novod		Jacob Martin Wiborg Rode
+45 3075 6050		+45 3075 5956
nvno@novonordisk.com		jrde@novonordisk.com
Max Ung		Sina Meyer
+45 3077 6414		+45 3079 6656
mxun@novonordisk.com		azey@novonordisk.com
Alex Bruce		Christoffer Sho Togo Tullin
+45 34 44 26 13		+45 3079 1471
axeu@novonordisk.com		cftu@novonordisk.com
Frederik Taylor Pitter		Mads Berner Bruun
+1 609 613 0568		+45 3075 2936
fptr@novonordisk.com		mbbz@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 29 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: May 5, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer